Blood and salivary-gland BAFF-driven B-cell hyperactivity is associated to rituximab inefficacy in primary Sjögren's syndrome

Article ID	Journal	Published Year	Pages	File Type
6119194	Journal of Autoimmunity	2016	9 Pages	PDF

Abstract

In pSS, half of the patients display an intense BAFF-driven B-cell activation and do not respond to a single course of rituximab.

Keywords

treatment efficacy primary BAFF Histology Rituximab B cells Sjögren's syndrome

Related Topics

Life Sciences Immunology and Microbiology Immunology

Preview

Blood and salivary-gland BAFF-driven B-cell hyperactivity is associated to rituximab inefficacy in primary Sjögren's syndrome

Authors

Divi Cornec, Sebastian Costa, Valérie Devauchelle-Pensec, Sandrine Jousse-Joulin, Pascale Marcorelles, Jean-Marie Berthelot, Laurent Chiche, Eric Hachulla, Pierre-Yves Hatron, Vincent Goeb, Olivier Vittecoq, Alain Saraux, Jacques-Olivier Pers,